LSD1-IN-26

• UNSPSC Description:

  LSD1-IN-26 (compound 12u) is a potent LSD1 inhibitor, with an IC50 of 25.3 nM. LSD1-IN-26 also inhibits MAO-A (IC50=1234.57 nM) and MAO-B (IC50=3819.27 nM). LSD1-IN-26 significantly induces apoptosis in MGC-803 cells. LSD1-IN-26 can be used for gastric cancer research[1].

• Target Antigen:

  Apoptosis; Bcl-2 Family; Caspase; Histone Demethylase; IAP; Monoamine Oxidase

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Epigenetics;Neuronal Signaling

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/lsd1-in-26.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O=C(N1CCN(CC1)C2=CC(Cl)=C(C=C2)Cl)C3=CC=CC(CN[C@@H]4C[C@H]4C5=CC=C(C(F)=C5)F)=C3

• Molecular Weight:

  516.41

• References & Citations:

  [1]Ma QS, et al. Discovery of novel tranylcypromine-based derivatives as LSD1 inhibitors for gastric cancer treatment. Eur J Med Chem. 2023 May 5;251:115228.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  3041141-72-1